UnknownPhase 2/3

Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction

Taiwan120 participantsStarted 2020-08-11

Plain-language summary

The investigators will conducted a randomized double-blind placebo-controlled study to investigate the treatment outcomes of add-on low dose dextromethorphan (DM), memantine (MM), or dextromethorphan and memantine combination (DM+MM) in amphetamine-type stimulants use disorder patients.

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent by patient or legal representative.
✓. Male or female patient aged ≧20 and ≦65 years.
✓. A diagnosis of ATSUD according to DSM criteria made by a specialist in psychiatry.
✓. Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.

Exclusion criteria

✕. Women of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study.
✕. Females who are pregnant or lactation.
✕. Other major Axis-I DSM-IV diagnosis other than ATSUD, except for tobacco use disorder, ATS induced mood or psychotic disorders.
✕. Current evidence of an uncontrolled and/or clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.
✕. History of allergy or intolerable side effects of DM or MM.
✕. Suicidal attempts or risks during screen or study period.
✕. Presence of active infectious or autoimmune disease.

What they're measuring

Urinary amphetamine positive rates

Timeframe: 12 weeks

Trial details

NCT IDNCT04687566

SponsorNational Cheng-Kung University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-31

Contact for this trial

Tzu-Yun Wang

+8862353535 tzuyun0105@hotmail.com

View on ClinicalTrials.gov More Amphetamine Addiction trials